Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Acquires 22,700 Shares of Company Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon bought 22,700 shares of Electra Therapeutics stock in a transaction that occurred on Tuesday, November 10th. The stock was bought at an average price of $8.45 per share, for a total transaction of $191,815.00. Following the completion of the acquisition, the director directly owned 5,255,278 shares of the company’s stock, valued at $44,407,099.10. The trade was a 0.43% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

Electra Therapeutics Stock Performance

Electra Therapeutics stock traded down $0.23 during mid-day trading on Tuesday, hitting $7.99. 298,185 shares of the stock were exchanged, compared to its average volume of 376,388. Electra Therapeutics, Inc. has a 12 month low of $6.86 and a 12 month high of $15.50.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set a “buy” rating and a $32.00 target price for the company. TD Cowen assumed coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set a “buy” rating on the stock. Zacks Research raised shares of Electra Therapeutics to a “hold” rating in a research report on Wednesday, October 14th. JPMorgan Chase & Co. assumed coverage on Electra Therapeutics in a report on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price target for the company. Finally, HC Wainwright began coverage on Electra Therapeutics in a research report on Monday, October 26th. They issued a “buy” rating and a $30.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $33.50.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRP?, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.